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Abstract 
The chemical synthesis of a gene coding for a polypeptide of 77 amino acid residues (designated ceaB3) representing a fragment of 
the CEA-B3 domain of carcinoembryonic antigen (CEA) was achieved. The ceaB3 fragment was cloned into the plasmid pLZPWB1 at 
the C-terminus of a derivative lacZMF of the lacZ gene, devoid of methionine and cysteine amino acid residues. The fusion protein 
lacZMF-ceaB3 represented approx. 30% of total proteins expressed after induction. The fusion protein was formed as inclusion bodies. 
Simple washing steps led to an insoluble fusion protein which was of approx. 80% purity. Another fusion gene was generated by inserting 
ceaB3 between the malE gene encoding maltose binding protein (mbp) and lacZa of the pmal-c2 vector. Expression of the resulting 
pmal-c2-ceaB3-1acZa yielded the fusion protein mbp-ceaB3-1acZa with a molecular mass of 57.94 kDa, which was obtained as a 
soluble protein in almost homogenous form after affinity chromatography employing amylopectin. Polyclonal sheep anti-CEA antiserum 
specifically reacted with fusion proteins lacZMF-ceaB3 and mbp-ceaB3-1acZa. A monoclonal antibody CEA/HK2 was generated 
employing lacZMF-ceaB3 for immunization and CEA for screening purposes. The mAB CEA/HK2 specifically recognized CEA in 
immunoblots. The described experimental strategy should be generally applicable for generation of fusion proteins. These fusion proteins 
are suitable for epitope characterization f existing antibodies, production of regiospecific polyclonal or monoclonal antibodies. 
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1. Introduction 
Carcinoembryonic antigen (CEA) was independently 
discovered by Gold and Freedman [1] and von Kleist and 
Burtin [2] to be present in colonic tumors as well as in 
fetal gut. Although CEA was also later found in normal 
body fluids and colonic mucosa of adults, CEA concentra- 
tions in tumor cases were on average significantly higher. 
A further complication is the existence of a large number 
of structurally related crossreacting antigens. However, 
CEA is still a widely employed parameter for monitoring 
cancer patients following treatment. A number of CEA-re- 
lated genes have now been identified by molecular cloning. 
The human CEA gene family is classified into two sub- 
groups, the CEA- and the pregnancy-specific glycoprotein 
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(PSG) subgroup. For an excellent overview, see Thomson 
et al. [3]. Proteins of the CEA subgroup are membrane 
proteins, anchored by a glycosyl phosphatidyl inositol 
moiety. The release of CEA-related proteins might be 
controlled by hydrolysis involving phospholipases [3]. 
CEA, like the CEA-related proteins, is built in a do- 
main-like structure [3]. Within a subgroup members reveal 
a high sequence conservation, whereas between subgroups 
the sequence homologies are significantly lower. Due to 
the high sequence similarity of CEA-related proteins and 
the limited number of accessible pitopes, it is evident hat 
the number of monoclonal antibodies pecific for CEA 
must also be limited. Other investigations concerned the 
localization of natural epitopes in CEA. Despite extensive 
glycosylation of CEA, most monoclonal antibodies recog- 
nize polypeptide epitopes [4]. Classification of CEA- 
specific epitopes made use of the expression of fusion-pro- 
teins with /3-galactosidase to characterize the epitope 
specificity of monoclonal antibodies [5]. Hass et al. [6] 
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expressed the four principal domains of CEA in Es- 
cherichia coli and employed the polypeptides to charac- 
terize the specificity of CEA-specific monoclonal antibod- 
ies. 
The problem of measuring the serum concentrations of 
CEA are two-fold: (1) specificity of monoclonal antibodies 
with the potential to discriminate between CEA and CEA- 
related proteins and (2) the calibration of different 
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Fig. 1. Synthesis of the DNA fragment encoding ceaB3. (A) DNA sequence encoding the peptide region comprising residues 561-637 of CEA. The 
N-terminal residues represented by italics are not part of the CEA sequence. (B) Sequence and location of primers P1 and PR9 employed in the reactions 
outlined in scheme D. (C) Sequence and locations of primers P6 and PR3 employed in the reactions outlined in scheme D. (D) Schematic representations 
of the steps leading to the synthesis of ceaB3 DNA. 
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immunological test systems due to the lack of a charac- 
terized CEA preparation. The latter is difficult to achieve 
because a homogenous large scale preparation of CEA 
from either tissue or cell cultures eems to be impossible. 
We describe in this investigation an approach which ad- 
dresses both problems. We identified by sequence compar- 
ison a 77 amino acid residue long fragment (designated 
ceaB3) of the B3 domain of CEA, which differed most 
significantly from other CEA-like proteins, especially non- 
specific rossreactive antigen (NCA) (see [3] for reference). 
A synthetic DNA gene encoding ceaB3 was generated and 
expressed as a fusion protein. The fusion protein contain- 
ing ceaB3 was employed both for the generation of mono- 
clonal antibodies and for a CEA-specific antigen. 
2. Materials and methods 
2.1. General 
Transformation of E. coli/XL-1 and E. col i /HBlO1 
was performed as published [7]. The yield of transforma- 
tion was generally about 2- 10 6 transformants//zg DNA. 
Recombinants were screened on replica nitrocellulose fil- 
ters (Millipore HATF) with a 32p-labeled hybridization 
probe (specific activity 2.108 cpm//xg DNA). Prehy- 
bridization and hybridization were performed according to 
Hanahan and Meselson [8] at 58°C. Positive clones were 
characterized by sequencing. Double strand DNA sequenc- 
ing was carried out by the dideoxy chain-termination 
method of Sanger et al. [9]. Oligonucleotides were synthe- 
sized using an Applied Biosystems DNA synthesizer model 
381A. A polyclonal antiserum against CEA was gener- 
ously provided by Prof. Dr. Miiller of Medizinische 
Akademie Dresden. 
2.2. Bacterial strains and plasmids 
E. coli XL-1/placZMFceaB3, E. coli XL-1/pmal-c2- 
ceaB3, E. coli HB101/pmal-c2-ceaB3-1acZot and E. coli 
XL-1/pUC18ceaB3 were grown in either LB-medium (10 
g Bacto-tryptone, 5 g Bacto-yeast extract and 10 g NaC1/I) 
or 2 x TY-medium (16 g Bacto-tryptone, 10 g yeast ex- 
tract and 5 g NaC1) containing 100 /xg/ml ampicillin. 
2.3. Synthesis of ceaB3-DNA 
Oligonucleotides P1 (10 /xg) and PR9 (10 /zg) were 
annealed at 37°C and the formed duplex subjected to a 'fill 
in' reaction using 10 units of DNA polymerase Klenow 
fragment and the following standard reaction mixture: 0.2 
mM dNTP in 50 mM Tris-HCl, pH 7.6, 100 mM KC1, 5 
mM MgCI 2 in a total volume of 100 /xl. Incubation was 
carried out for 1 h at 37°C. A similar experiment was 
performed using the oligonucleotides P6 and PR3. The 
sequences of the oligonucleotides mployed in these reac- 
tions were depicted in Fig. 1. The formed fragments #19 
and #63 were purified by polyacrylamide gel elec- 
trophoresis in 5% gels under standard conditions. Frag- 
ments #19 and #63 (2 /zg each) were mixed in the same 
buffer as above, heated to 90°C, cooled quickly to 37°C 
and subjected to 'fill in' reaction under conditions as 
described above. The reaction mixture was analyzed by 
agarose gel electrophoresis; a fragment of the appropriate 
size of 250 bp was purified from the agarose gel and 
ligated into a pUC18 vector estricted with SmaI, employ- 
ing the following standard ligation reaction (mixture con- 
taining 50 mM Tris-HCl, pH 7.5, 10 mM DTT, 10 mM 
MgC12, 1 mM ATP, 25 /zg/ml BSA, 4 units T4-DNA 
ligase and incubation at 15°C for 15 h). Competent E. coli 
XL-1 were transformed with the ligation mixture and the 
cells plated on LB-agar containing 100 /xg/ml ampicillin. 
Positive recombinant clones were detected by colony hy- 
bridization. Plasmid was prepared from 9 positive clones 
and subjected to double stranded sequencing. Two positive 
clones harboured plasmids which contained ceaB3-DNA 
with the correct sequence. The plasmid construct was 
named pUC18ceaB3. 
2.4. Construction of placZMFceaB3 
The vector pUC18ceaB3 was cut with EcoRI/BamHI, 
the resulting ceaB3-fragment was purified by agarose gel 
electrophoresis and blunt ended by 'fill in' reaction under 
standard conditions, pLZPWB1 [10] was restricted with 
BamHI/HindIII and sticky ends were blunt ended by 'fill 
in' reaction. The cut vector pLZPWB1 and the blunt ended 
ceaB3-DNA fragment were ligated in a reaction mixture 
containing 50 mM Tris-HC1, pH 7.5, 10 mM DTI', 10 mM 
MgC12, 1 mM ATP, 25/zg/ml BSA and 4 units T4-DNA 
ligase at 15°C for 15 h. This ligation mixture was directly 
employed to transform E. coli XL-1 using standard condi- 
tions [11,12]. Recombinant cells harbouring plasmids with 
ceaB3-DNA inserts were detected by colony hybridization. 
From positive recombinant cells, plasmids were isolated 
and subjected to double stranded sequencing. The plasmid 
containing the ceaB3 DNA fragment of correct sequence 
and in the proper reading frame was designated placZM- 
FceaB3. 
2.5. Preparation of lacZMF-ceaB3 
An overnight culture (20 ml) of E. coli XL- 
1/placZMFceaB3 in LB/amp was used to inoculate 2 1 of 
LB/amp. After growth at 37°C to an OD (600 nm) of 0.5 
the expression of the fusion protein was induced by addi- 
tion of IPTG to a concentration of 1 raM. After 3 h at 
37°C, the cells were harvested by centrifugation. The wet 
weight of the cell pellet was 7.2 g. The cell pellet was 
resuspended in 30 ml of 20 mM sodium phosphate buffer, 
pH 6.5 and the cells were then disrupted by sonication for 
two times 1 rain at full power under cooling with ice. The 
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suspension was centrifuged for 20 min at 12 000 rpm in a 
Beckman centrifuge mploying a JA20 rotor. The pellet 
was suspended by sonication in 20 mM phosphate buffer, 
pH 6.5 containing 0.5% Triton X-100 and 1 mM EDTA. 
The suspension was centrifuged as described above and 
the procedure of resuspension repeated. The pellet was 
then dissolved in 8 M urea containing 10 mM DTI" 
employing sonication. Insoluble particles were removed by 
centrifugation as described above. The supernatant was 
removed and the fusion protein was precipitated from the 
solution by diluting with 100 mM phosphate buffer, pH 
6.0 to 3 M urea. The precipitate was centrifuged off as 
described and the remaining pellet washed successively 
with 20 mM phosphate buffer, pH 6.0 containing 3 M urea 
and finally with water. Sodium azide was added to the 
suspension up to a concentration of 0.1%. Lyophilization 
yielded 120 mg of fusion protein. 
2.6. Cleavage of lacZMF-ceaB3 with cyanogen bromide 
lacZMF-ceaB3 fusion protein (50 mg) was solubilized 
in 70% trifluoroacetic acid (TFA) (5 ml). A solution of 
cyanogen bromide (300 mg) in 70% TFA (1 ml) was 
added to the fusion protein. The solution was stirred at 
room temperature in the dark for 24 h. The proteins were 
precipitated from the solution by 10 volumes of ether, 
centrifuged and dried. The pellet was solubilized in a 
buffer of 50 mM Tris-HCl, pH 8.3 and 8 M urea. The 
cleaved IacZMF part of the fusion protein was precipitated 
from the solution by dilution to 2 M urea with 100 mM 
Tris-HCl pH 5.7 and centrifuged. The supernatant, contain- 
ing the ceaB3 portion of the fusion protein was dialyzed 
against 10 mM Tris-HCl pH 7.5, 50 mM NaC1. 
2.7. Construction of pmal-c2-ceaB3 and pmal-c2-ceaB3- 
lacZa 
The ceaB3 DNA fragments for both constructions were 
prepared from placZMFceaB3 by polymerase chain reac- 
tion (PCR). PCR was carried out in the following manner: 
3 min 94°C (start); 2 min 94°C, 3 min 50°C, 1 s 72°C (40 
cycles); 10 min 72°C (end). The reaction mixture con- 
tained: 0.2 pmol placZMFceaB3, 100 pmol each of for- 
ward and reverse primer (forward primer for both con- 
structions was the same, only the reverse primer differed), 
25 nmol dNTPs, 10 mM Tris-HC1 pH 8.3, 1.5 mM MgC12, 
50 mM KC1, 1 mg/ml  gelatine and 2.5 U Taq poly- 
merase. The reaction volumes were for both constructions 
100 /xl. The amplified ceaB3 fragments were restricted by 
HinclI and HindlII. Vector pmal-c2 was restricted by 
XmnI and HindlII. The cut pmal-c2 and each of the ceaB3 
fragments were ligated, employing conditions as described 
above for the construction of placZMFceaB3, and the 
resulting mixture was used to transform competent E. coli 
strains. The E. coli strain XL-1 was used in both construc- 
tions, the strain HB101 only in construction of pmal-c2- 
ceaB3-1acZ or. Recombinant cells harbouring plasmids with 
inserts were detected by colony hybridization. From posi- 
tive recombinant cells, plasmids were isolated and sub- 
jected to double strand sequencing. The plasmid containing 
the ceaB3 fragment with the stop codon at the end of the 
ceaB3 sequence in the proper reading frame and correct 
sequence was designated pmal-c2-ceaB3. The other plas- 
mid containing the correct sequence of the ceaB3 fragment 
without a stop codon and in the proper reading frame for 
the following lacZ c~ gene was designated pmal-c2-ceaB3- 
lacZ c~. 
2.8. Preparation of mbp-ceaB3 
1 1 of LB/amp was inoculated with an overnight cul- 
ture (20 ml) of E. coli XL-1/pmal-c2-ceaB3. After growth 
at 37°C up to a cell density of OD (600 nm) 0.5 the 
expression of the fusion protein was induced by addition 
of IPTG to a concentration of 0.3 mM. The culture was 
incubated for 3 h at 37°C and then harvested by centrifuga- 
tion. The cell pellet (6.6 g) was resuspended in 50 ml lysis 
buffer containing 10 mM sodium phosphate pH 7.0, 30 
mM NaCl, 0.25% Tween 20, 10 mM /3-mercaptoethanol, 
10 mM EDTA, 10 mM EGTA and 1 mM PMSF. The 
suspension was sonicated for two times 30 s. After centrif- 
ugation for 30 min at 10000 rpm, 4°C in a Beckman 
centrifuge using a JA20 rotor, the supernatant was adjusted 
to 500 mM NaC1 and diluted five times with affinity 
column buffer (10 mM Tris-HC1, pH 7.2, 500 mM NaCI). 
The diluted supernatant was run to an affinity chromatog- 
raphy column of amylose resin. The column was washed 
with 10 column volumes of affinity column buffer. The 
fusion protein was eluted with a buffer containing 10 mM 
Tris-HC1, pH 7.5, 500 mM NaCI, 10 mM maltose, 1 mM 
EDTA and then dialyzed against 10 mM Tris-HC1 pH 8.0, 
100 mM NaC1. The yield was 30.5 mg of mbp-ceaB3 
fusion protein. 
2.9. Preparation of mbp-ceaB3-lacZa 
1 1 of LB/amp was inoculated with 20 ml of an 
overnight culture of E. coli HB101/pmal-c2-ceaB3-1acZa 
and incubated at 37°C until a cell density of OD (600 nm) 
0.5 was achieved. The expression of the fusion protein was 
then induced by addition of IPTG to a concentration f 0.3 
mM, Incubation was continued for 3 h at 37°C and then 
cells were harvested by centrifugation. The cell pellet (2.3 
g) was resuspended in 40 ml of a buffer containing 20 mM 
Tris-HC1, pH 7.5, 200 mM NaCI, 10 mM fl-mercapto- 
ethanol and 1 mM EDTA. The suspension was sonicated 
for two times 30 s. The mixture was centrifuged 30 min at 
4°C and 10 000 rpm in a Beckman centrifuge using a JA14 
rotor. The supernatant was removed and 3 g amylopectin 
(A-7780, Sigma) was added to it under vigorous shaking. 
The mixture was kept on ice for 30 min. The amylopectin 
was separated by centrifugation at 10 000 rpm for 30 min 
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in at 4°C. The supernatant was discarded and the pellet 
washed with 40 ml of a buffer containing 20 mM Tris-HC1, 
pH 7.5, 200 mM NaC1, 10 mM /3-mercaptoethanol, 1 mM 
EDTA, 0.1% Tween 20 and two times in the same buffer 
without Tween 20 under suspension. After centrifugation 
as described above, the pellet was eluted with 10 ml of a 
solution containing 20 mM Tris-HCl, pH 7.5, 200 mM 
NaC1, 10 mM /3-mercaptoethanol, 1 mM EDTA and 0.5 M 
maltose. The yield was 20 mg of mbp-ceaB3-1acZa. 
2.11. Gel electrophoresis and immuno-blotting 
Sodium dodecylsulfate polyacrylamide gel elec- 
trophoresis (SDS-PAGE) [13] and immuno-blotting after 
SDS-PAGE followed a published protocol [14]. For im- 
munodetection of sheep IgGs or mouse IgGs, the blots 
were incubated with either peroxidase-conjugated goat 
anti-sheep antibodies or sheep anti-mouse antibodies 
(Amersham). 
2.10. Generation of the monoclonal antibody HK2 2.12. Sequence data analysis 
Female Balb/C mice were immunized with a suspen- 
sion of lacZMF-ceaB3 employing standard protocols. 
Mouse spleen cells were fused with the mouse myeloma 
cell line P3-X63Ag8 by standard techniques. Hybridomas 
were cloned by limited dilution. Screening was performed 
employing a direct ELISA employing CEA as antigen. A 
positive clone CEA/HK2 was characterized asIgGI(K); a 
culture supernatant with an IgG concentration f 15/xg/ml 
had a titer of 1:104 in the direct ELISA. The CEA-specific 
mAB CEA/HK2 reacted in Western blots with lacZMF- 
ceaB3, mbp-ceaB3-1acZa as well as with CEA. The mo- 
noclonal antibody reacted with CEA in a direct ELISA 
employing concentrations a low as 0.6 ng/ml. 
DNA and protein sequence analysis were performed 
using the computer program of the University of Wiscon- 
sin genetics computer group [15]. 
3. Results  
3.1. Synthesis of ceaB3 DNA 
The polypeptide sequence of 77 residues from the CEA- 
B3 domain was chosen because sequence comparison i di- 
cated that it showed the least identity to the other sequence 
domains in CEA. The sequence of the polypeptide repre- 
I ceaB3 I 
placZMFceaB3 ~ / 
3912 bp I 
lacZMF 5 
\ ~ plac / /  
f 
pUC 18/Smal \ 
blunt ended / 
Jg~- -  ------,~'~ BamHl 
lacZ'   
JUC18ceaB3 I \ 






I ceaB3 fragment ] 
Hindlll i 
Sinai 
3667 bp ;' 
,\ plac / /  
/ 
Fig. 2. Schematic representation of the steps leading to the construction f placZMFceaB3. The DNA as well as the deduced amino acid sequence of the 
C-terminal region of the lacZMFceaB3 is shown in Fig. 6. 
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senting a fragment of the CEA-B3 domain ranging from 
residue 561-637 (designated ceaB3) is shown in Fig. 1A. 
The experimental strategy to generate a fusion protein 
comprising the ceaB3 involved the chemical synthesis of a 
gene coding for ceaB3 and the integration of the synthetic 
DNA fragment into the plasmid pLZPWB1 at the C- 
terminus of a gene coding for a special protein, devoid of 
methionine and cysteine amino acid residues. This gene 
was derived from the lacZ gene, in which all methionine as 
well as cysteine residues have been substituted by muta- 
tion [10]. This strategy appeared to be attractive for the 
following reasons: expression of the fusion gene would be 
inducible and the fusion gene lacZMF-ceaB3 would be 
insoluble and easy to purify. 
The sequence of the synthetic DNA was devised em- 
ploying E. coli codon usage. The synthesis of ceaB3 DNA 
was achieved as follows. Four synthetic oligonucleotides 
# l ,  #6, #9 and #3 representing parts of the sequence of 
ceaB3 DNA (see Fig. 1) were hybridized, and the single 
stranded gaps which formed were filled by primer exten- 
sion employing the DNA polymerase Klenow fragment to 
yield the blunt ended double stranded fragments #19 and 
#63 (see Fig. 1D). The two fragments #19 and #63, 
which comprised the ceaB3 DNA from position 1-177 and 
77-250 respectively, were denatured in a second step, 
rehybridized and the resulting hybrids filled in with Klenow 
fragment to yield the complete ceaB3 DNA (see Fig. 1D). 
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Fig. 4. Immunoreactivity of the fusion protein lacZMFceaB3 with anti- 
CEA antiserum. Total protein mixtures obtained from E. coli XL- 
1/placZMFceaB3 were separated bySDS-PAGE using a 12% gel and 
electrophoretically transferred onto a membrane. The transferred proteins 
were subjected toimmunoreaction employing sheep anti-CEA antiserum 
as described in Materials and methods. Lanes 4 and 5 of the membrane 
were stained for proteins by ColAurion. Lane 1, induced; lane 2, unin- 
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Fig. 3. Expression ofplacZMFceaB3. Total protein mixtures of E. coli 
XL-1/placZMFceaB3 after various times of induction by IPTG were 
subjected to SDS-PAGE. Lane 1, 30 min; lane 2, 60 rain; lane 3, 120 
min; lane 4, 180 min; lane 5, uninduced. 
earized by SmaI treatment and the reaction mixture em- 
ployed to transform E. coli. Recombinant E. coli cells 
harbouring pUC18ceaB3 were detected by colony hy- 
bridization. From 9 positive clones only two were shown 
by sequencing to contain the complete sequence of ceaB3 
DNA. 
3.2. Construction and expression of  the fusion gene 
lacZMFceaB3 
The construct pUC18ceaB3 was the basis for the further 
construction of a fusion gene in plasmid pLZPWB1. The 
experimental steps leading to construct placZMFceaB3 are 
represented schematically in Fig. 2: 
(a) Restriction of pLZPWB1 with BamHI /H ind l l I  and 
blunt-end formation by 'fill-in' using Klenow frag- 
ment; 
(b) restriction of pUC18ceaB3 with EcoRI /BamHI  and 
isolation of the EcoRI-BamHI fragment containing the 
ceaB3 DNA; 
(c) the ceaB3 DNA EcoRI-BamHI fragment was blunt- 
ended by fill-in with Klenow fragment; 
(d) ligation of the blunt end ceaB3 DNA EcoRI-BamHI 
fragment into blunt-ended pLZPWB1 and transforma- 
tion of E. coli strain XL-1 with the ligation mixture. 
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Fig. 5. Fragmentation f the fusion protein lacZMF-ceaB3 by CNBr: 
Analysis by SDS-PAGE and immunoblot. Protein mixtures were sepa- 
rated by SDS-PAGE and electrophoretically transferred onto a membrane. 
Lanes 1 and 3-6, were stained for proteins with India ink. The proteins in 
lanes 8-11 subjected to immunoreaction with sheep anti-CEA antiserum. 
Lane 1, marker proteins; lane 3 and 8, CNBr-reaction, soluble proteins; 
lane 4 and 9, CNBr-reaction, insoluble protein fraction; lane 5 and 10, 
CNBr-reaction, total reaction mixture; lane 6 and 11, fusion protein 
lacZMF-ceaB3. 
Positive recombinants harbouring plasmid constructs 
placZMFceaB3 were detected by colony hybridization; 19 
out of 24 colonies were positive. 
The correct sequence of placZMFceaB3 was verified by 
sequencing. The obtained sequence showed that a fusion 
gene was generated which contained the ceaB3 DNA 
fragment in a reading frame with the C-terminus of the 
modified IacZMF gene. 
The growth curve of placZMceaB3 was apparently 
normal; no indication was given of an inhibition of growth 
Fig. 6. Generation of the ceaB3 DNA fragment for the construction of 
pmal-c2-ceaB3. The sequence represents part of the fusion gene of 
placZMFceaB3. The nucleotides in lower print are from the original 
pLZPWBI sequence, those in lower print and italics are derived from 
pUC18. Employing the two primers of indicated location, a PCR frag- 
ment was amplified. The fragment contained a Hincll site at 5' and a 
HindllI site at the 3' end. These two restriction sites are underlined in the 
primer sequences. The generated fragment represents a modified ceaB3 
fragment with an aspartate residue (underlined, bold print) at the N- 
terminus instead of a methionine r sidue. 
by expression of the fusion gene (data not shown). The 
fusion protein lacZMF-ceaB3 displayed an apparent 
molecular mass of approx. 60 kDa, in accordance with the 
theoretical molecular mass as calculated from the amino 
acid sequence. The lacZMF-ceaB3 represented approx. 
30% of the protein species expressed after induction (Fig. 
3). Employing a polyclonal sheep anti-CEA antiserum, it 
could be shown that lacZMF-ceaB3 was the only immuno- 
reactive protein present (Fig. 4). The fusion protein, as 
expected, was formed as insoluble inclusion bodies. Sim- 
ple washing steps led to an insoluble fusion protein which 
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Fig. 7. Schematic representation f the steps leading to construction ofpmal-c2-ceaB3. The sequence of the HinclI/Hindlll ceaB3 fragment is shown in 
Fig. 6. 
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ggat t ggt ggcgacgact  oct ggagcccgt  cagt at cggcggaat  t cgagct  cgcccggg 
I G G D D S W S P S V S A E F E L A R G 
CCATCgTcaacACCCCGATCATCTCTCCGC- -  - > 3 ' 
gat cgatccCcATCCTGATGACCCCGATCATCTCTCCGCCGGACTCTTCTTACCTGTCTG 
S I P I S D T P Z Z S P P D S $ T L 8 G 
GTGCTAACCTGAACCTGTCTTGCCACTCTGCTTCTAACCCGTCTCCGCAGTACTCTTGGC 
A N L N L S C H S A S N P S P ~Q 3~ S W R 
GTATCAACGGTATCCCGCAGCAGCACACCCAGGTTC TGTTCATCGCTAAAATCACCCCGA 
I N G I P Q Q H T Q V L P I & K I T P N 
3 ' <---CATTGTTGAGAT 
ACAACAACGGTACCTACGCTTGCT TCGTTTCCAACC TGGCTACCGGTCGTAACAACTCTA 
H N G T • & C F V S N L A T O R N N S r 
~T '£ 'T t  aecgTt  caaaCgccc  
TCGTTAAATCTTAATAAGgggtaccgagctcgaat tagct  t cgcgat  goat  cagat ct ac 
V K II 
ca tggcatgccaat t  c 3916 
Fig. 8. Generation of the ceaB3 * DNA fragment for the construction f 
pmal-c2-ceaB3-1acZa. The sequence r presents part of the fusion gene of 
placZMFceaB3. The nucleotides in lower print are from the original 
pLZPWB1 sequence, those in lower print and italics are derived from 
pUC18. Employing the two primers of indicated location, a PCR frag- 
ment was amplified. Tile fragment contained a HinclI site at 5' and a 
HindlII site at the 3' end. These two restriction sites are underlined inthe 
primer sequences. The generated fragment represents a modified ceaB3 *
fragment with an aspartate r sidue (underlined, bold print) at the N- 
terminus instead of the metbionine r sidue and a C-terminal methionine 
(underlined, bold print) instead of a serine residue. 
design of the lacZMF-ceaB3 allowed the cleavage of the 
ceaB3 fragment from the fusion protein by CNBr treat- 
ment (Fig. 5). This procedure led to the disappearance of
the immunoreactive intact lacZMF-ceaB3 and to the for- 
mation of an insoluble core protein of approx. 52 kDa 
which had lost the immunoreactivity towards anti-CEA 
antiserum. Soluble fractions retained the immunoreactivity 
as had been predicted. 
3.3. Construction and expression of the fusion gene malE- 
ceaB3 
Using placZMFceaB3 and the two primers located as 
shown in a partial sequence comprising ceaB3 (Fig. 6), a 
DNA fragment was amplified by PCR which possessed a
HinclI site at the 5' and a HindlII site at the 3' end. The 
use of modified primers led to the amplification of a DNA 
fragment with an aspartate residue at the N-terminal region 
of the ceaB3 fragment. This additional amino acid residue 
corresponds to the CEA sequence. The obtained ceaB3 
DNA fragment was cloned into pmal-c2 restricted with 
XmnI and HindllI. This resulted in the generation of a 
fusion gene malE-ceaB3, encoding the maltose binding 
protein fused to ceaB3 (designated mbp-ceaB3). The indi- 
vidual steps of this construction are illustrated in Fig. 7. 
The expression of the fusion gene malE-ceaB3 led to the 
fusion protein mbp-ceaB3 with a molecular mass of 50.8 
kDa. Unfortunately, a lot of smaller immunoreactive frag- 
ments were observed in an immunoblot with anti-ceaB3 
mAB CEA/HK2.  By the pattern of this fragments and by 
the possibility of purification by affinity chromatography 
on amylose resin it can be hypothesized that this is proteol- 
ysis of ceaB3 part of the fusion protein mbp-ceaB3. A 
soluble fusion protein with a protected ceaB3 part was 
therefore decided upon. 
3.4. Construction and expression of pmal-c2-ceaB3-1acZa 
Using placZMFceaB3 and two primers located as shown 
in the partial sequence in Fig. 8 a DNA fragment was 
amplified by PCR, which possessed a HincII site at the 5' 
and a HindlII site at the 3' end. The modified primers led 
to the amplification of a DNA fragment, in which besides 
restriction sites the C-terminal amino acid sequence was 
modified by changing serine into methionine and by re- 
moving the stop codons. The obtained modified ceaB3 
fragment (designated ceaB3*) was cloned into pmal-c2 
restricted with XmnI and HindlII. The individual steps of 
construction of pmalE-ceaB3-1acZ a are detailed in Fig. 9. 
Expression of pmal-c2-ceaB3-1acZa in E. coli XL-1 led 
to the formation of an insoluble protein of approx, molecu- 
lar mass 60 kDa as the major species. The theoretical 
molecular mass of the fusion protein mbp-ceaB3-1acZ a is 
57.94 kDa. This major protein was found to be soluble 
when the expression was done in E. coli HB101, which 
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Fig. 9. Schematic representation of the construction f pmal-c2-ceaB3-1acZa. 
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Fig. 10. Gene expression f pmal-c2-ceaB3-1acZot: Analysis by SDS- 
PAGE. Proteins isolated from cultures of E. coli HB101/ 
pmalEceaB31acZa induced by 1PTG, were analyzed by SDS-PAGE. 
Lane 1, molecular weight standards; lane 2 to 5, total proteins 0,60, 120 
and 180 min after induction by IPTG; lane 6, insoluble proteins; lane 7, 
soluble proteins; lane 8, mbp-ceaB3-1acZa fusion protein purified by 
affinity chromatography. 
could be isolated by affinity chromatography employing 
amylopectin in almost homogeneous form (Fig. 10). The 
fusion protein turned out to be reactive with anti-ceaB3 
mAB CEA/HK2 when probed in an immunoblot (Fig. 
11). 
1 2 3 4 5 6 7 
Fig. 11. lmmunoreactivity of the anti-ceaB3 mAB CEA/HK2. Proteins 
were separated bySDS-gel electrophoresis and electrophoretically trans- 
ferred onto a membrane. Lanes 1 to 5, immuno blot; lanes 6, 7, proteins 
stained with ColAurion; lane 1, mbp; lane 2, IacZMF; lane 3, CEA; lane 
4, mbp-ceaB3-1acZa; lane 5, lacZMF-ceaB3; lane 6, mbp-ceaB3-1acZa; 
lane 7, total protein mixture of E. coli XL-1/placZMFceaB3 after 
induction. 
3.5. Monoclonal  mouse anti-ceaB3 antibody CEA / HK2 
Specificity of the mouse anti-ceaB3 mAB CEA/HK2 
was investigated by immunoblots. As shown in Fig. 11, 
mAB CEA/HK2 reacted with CEA, lacZMF-ceaB3 and 
mbp-ceaB3-1acZce. The mAB CEA/HK2 did not react 
with either lacZMF or mbp-lacZa. 
4. Discussion 
The synthetic gene ceaB3 was successfully cloned in 
various vectors yielding constructs with fusion genes. Con- 
struct placZMF-ceaB3 led to expression of insoluble fu- 
sion protein in the form of inclusion bodies. The easily 
purified lacZMF-ceaB3 was employed for the generation 
of monoclonal antibodies and it could be shown that latter 
reacted with the intact CEA molecule. Attempts to express 
a soluble fusion protein mbp-ceaB3 turned out to be 
unsuccessful, because of the susceptibility of the fusion 
product against proteolytic degradation. Only the construc- 
tion of a fusion gene embedding the ceaB3 between mbp 
and lacZa leading to expression of the fusion protein 
mbp-ceaB3-1acZa provided a high yield of soluble pro- 
tein. A general advantage is that proteolytic degradation of 
the desired antigen within the fusion protein is unlikely. 
Therefore, sophisticated proteinchemical sequence verifica- 
tions of fusion proteins are in most cases unnecessary. It 
appears that this strategy for the design and expression of 
soluble fusion proteins might be generally applicable. 
The described mouse anti-ceaB3 mAB is the first di- 
rected against a short peptide region of the CEA protein 
which also displayed immunoreactivity against he whole 
CEA protein. In this context, it is necessary to recall the 
amino acid sequence of ceaB3 which comprises a loop 
structure formed by a disulfide bridge. Furthermore, it 
contains three putative N-glycosylation sites. That an mAB 
directed against his 77 residue fragment also reacted with 
epitopes from this region in the whole CEA confirms the 
notion that the majority of epitopes of the heavily glyco- 
sylated CEA molecule are of peptidic nature. 
Fusion proteins containing relatively large protein re- 
gions of the CEA molecule have already been employed to 
characterize the epitope specificity of CEA-specific mABs 
[3]. The approach described above aimed at the use of 
fusion proteins containing the ceaB3 region to achieve the 
generation of CEA-specific mABs. This goal could be 
achieved. It has still to be shown whether these antibodies 
can be employed in immunological test systems uch as 
enzyme linked immunosorbent assays or immunoradiomet- 
tic assays. 
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